Oxurion NV broadcasts the appointment of Adrienne Graves on its Board of Administrators
Louvain, Belgium, October 29, 2018 / PRNewswire / –
Oxurion NV (Euronext Brussels: OXUR – previously generally known as ThromboGenics Nevada), a biopharmaceutical firm that develops modern remedies to protect imaginative and prescient within the eyes of sufferers with eye ailments, at the moment introduced the appointment of Adrienne Graves, Ph.D., to its board of administrators. Dr. Graves will substitute Paul howes, who has been a board member since 2014.
"I'm honored to be named for the blackboard of administrators in Oxurion, " mentioned Dr. Critical "The corporate has constructed a various portfolio of therapies that modify the illness, reminiscent of The present pipeline focuses on diabetic eye illness. The chief staff of Oxurion. HAVE Superior expertise and information, and I hope to work with them up shut. "
Thomas Clay, Administration Counsel President from Oxurion NV, added: "As acknowledged whole Chief within the ophthalmology business, Dr. Graves brings intensive expertise to our board of administrators. we I hope to work along with her like us proceed working develop remedies protect sufferers the imaginative and prescient. On the similar time, I wish to take the chance to thank Paul Howes on your help and recommendation. over final oven years ".
Dr. Graves is a board member of a number of firms and organizations, together with Akorn Inc., Nicox, the American Society of Cataract and Refractive Surgical procedure, the Glaucoma Analysis Basis and the American Academy of Ophthalmology. She was the president and CEO of Santen Inc., the USA. UU Japan The most important ophthalmology pharmaceutical firm, Santen Pharmaceutical Co., Ltd. Earlier than turning into president and chief government officer, she was vp of medical affairs and senior vp of medical affairs all over the world. Japan, USA Y Europe at Santen Inc. Previous to Santen Inc., Dr. Graves was director of worldwide ophthalmology at Alcon Laboratories, Inc. She was additionally co-founder of Glaucoma 360 (Glaucoma Analysis Basis) and Ophthalmic Girls Leaders (OWL). Dr. Graves acquired a bachelor's diploma in psychology with honors from Brown College, his doctorate from College of Michigan in psychobiology and postdoctoral fellowship in visible neuroscience on the College of Paris.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm that develops remedies to protect imaginative and prescient in sufferers with eye issues. The corporate has created a various portfolio of therapies that modify the illness, together with remedies for diabetic eye illness, one of many main causes of blindness in folks of all ages.
The Oxurion medical line consists of THR-317, an inhibitor of PlGF, for the therapy of diabetic macular edema (DME) and MacTel1; THR-149, inhibitor of plasma kallikrein for the therapy of DME; and THR-687, a pan-RGD integrin antagonist for the therapy of diabetic retinopathy and DME. At the moment, new candidates for brand spanking new medication for the therapy of diabetic eye illness are being evaluated.
Oxurion owns the worldwide rights of JETREA.® (ocriplasmin), the one pharmacological drug for vitreolysis accepted for the therapy of symptomatic vitreomacular adhesion (within the US) and vitreomacular traction (outdoors the US).
Oxurion is predicated in Leuven, Belgium, the change is below the image OXUR. Within the USA UU., Oxurion NV operates ThromboGenics, Inc. as a subsidiary firm. Extra data is accessible at http://www.oxurion.com.
Vital details about forward-looking statements
Sure statements on this press launch could also be thought of "To future". These forward-looking statements are based mostly on present expectations and, because of this, are influenced by numerous dangers and uncertainties. The Firm can’t present any assure that such forward-looking statements will materialize and assumes no obligation to replace or revise forward-looking statements, whether or not new data, future occasions or every other cause. Extra data associated to enterprise dangers and uncertainties and different components which may be current within the Firm's Annual Report. This press launch doesn’t represent a proposal or buy of securities or property of Oxurion in any jurisdiction. Oxurion securities can’t be provided or offered inside the USA With out registration below the US Securities Act. UU Of 1933, as amended, or in accordance with an exemption therefrom, and in accordance with the state securities legal guidelines of the US. UU
For extra data contact:
World Director of Corp Coms and Investor Relations
+ 32-16-75-13-10 / + 32-478-33-56-32
EU – Rogerson Citigate Dewe
David Dible / Sylvie Berrebi
Tel: +44 (0) 20-7638-9571
United States – Public Relations lifesci
SOURCE Oxurion NV